RNA Binding Protein RNPC1 Suppresses the Stemness of Human Endometrial Cancer Cells via Stabilizing MST1/2 mRNA

Wu, Xingmei; Wang, Yonghui; Zhong, WeiJuan; Cheng, HuiFei; Zou, Tian

doi:10.12659/msm.921389

Cited by 5 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AGR3 modulates Wnt/β-catenin pathway in colorectal cancer to accelerate the stemness [29]. RNPC1 stabilizes MST1/2 mRNA to reduce the stemness in endometrial cancer [30]. In our study, it was confirmed that NMT1 facilitated the stemness in NSCLC.…”

Section: Discussionsupporting

confidence: 73%

NMT1 Enhances the Stemness of NSCLC Cells by Activating the PI3K/AKT Pathway

Zou¹,

Zhang²,

Wang³

et al. 2022

Pharmacology

View full text Add to dashboard Cite

Introduction: Abundant studies have disclosed that proteins can function as pivotal tumor promoters or suppressors in cancers’ progression. This work was planned to investigate the regulatory function of N-myristoyltransferase-1 (NMT1) on non-small cell lung cancer (NSCLC) and the underlying molecular mechanisms. Methods: The self-renewal abilities were assessed through a spheroid-formation assay. The tumorigenic abilities were examined through nude mice in vivo assay. The proteins’ expression was measured through Western blot. The NMT1 protein expression in tumor tissues was measured through an IHC assay. The cell migration and invasion was confirmed through a transwell assay. The IC50 was verified through a CCK-8 assay. The NMT1 mRNA expression in NSCLC tissues was detected through RT-qPCR. Results: It was demonstrated that NMT1 exhibited higher expression in spheroid cells. Additionally, NMT1 facilitated the stemness in NSCLC. It was also found that NMT1 accelerated NSCLC tumor metastasis and the resistance to cisplatin. Moreover, NMT1 activated the PI3K/AKT pathway to facilitate stemness in NSCLC. NMT1 was also higher in tumor tissues of NSCLC patients and resulted in a poor survival rate. Conclusion: NMT1 enhanced the stemness of NSCLC cells by activating the PI3K/AKT pathway. This discovery suggested that NMT1 may be a valid therapeutic biomarker for NSCLC.

show abstract

Section: Discussionsupporting

confidence: 73%

NMT1 Enhances the Stemness of NSCLC Cells by Activating the PI3K/AKT Pathway

Zou¹,

Zhang²,

Wang³

et al. 2022

Pharmacology

View full text Add to dashboard Cite

show abstract

“…19 For example, Musashi-1 inhibits the malignant characteristics of ovarian cancer and reverses paclitaxel resistance 20 ; ESRP1 is upregulated in ovarian cancer and promotes the transformation of ovarian cancer cells from an interstitial phenotype to an epithelial phenotype 21 ; and the stemness of EC cells is inhibited by the RBP RNPC1 by stabilizing MST1/2 mRNA. 22 However, the role of the most RBPs in EC remains unclear. A systematic functional analysis of RBPs will help to further study their role in EC.…”

Section: Introductionmentioning

confidence: 99%

Prognostic Values From Integrated Analysis of the Nomogram Based on RNA-Binding Proteins and Clinical Factors in Endometrial Cancer

Yuan

Sun

Wang

2022

Clin Med Insights Oncol

View full text Add to dashboard Cite

Background: Endometrial cancer (EC) is a common gynecological malignancy, and the prognosis of advanced EC is unsatisfactory. The deregulated expression of RNA-binding proteins (RBPs) is closely associated with the occurrence and development of cancer. However, the role of RBPs in EC remains unclear. The aim of this study was to validate the prognostic values of RBPs combined with clinical factors. Methods: We downloaded the RNA sequencing and clinical data for EC from The Cancer Genome Atlas (TCGA) database. R software was used to identify the differentially expressed RBPs. Univariate and multivariate Cox proportional hazards regression analyses were performed to predict the 4 overall survival (OS)-related RBPs. We then constructed a nomogram combining the 4-RBP signature with clinical risk factors to assess the prognostic power. Furthermore, we validated the expression of 4 RBPs in our patient samples using quantitative real-time polymerase chain reaction (qRT-PCR) and explored the effect of cold-inducible RNA-binding protein (CIRBP) on EC tumor growth using cell proliferation experiments. Results: It is found that Shwachman-Bodian-Diamond syndrome (SBDS), CIRBP, MRPL15, and CELF4 were significantly related to the prognosis of EC patients. In addition, the nomogram showed better performance in OS predictions than the International Federation of Gynecology and Obstetrics (FIGO) stage. The qRT-PCR results showed that low CIRBP expression was associated with cell proliferation. Conclusions: In our study, we constructed a 4-RBP signature-based nomogram combined with clinical factors in EC that could effectively predict the prognosis of EC patients. The results provide novel insights into the development of treatment targets and prognostic molecular markers in EC.

show abstract

“…The proliferation, migration, and invasion of EC cells were decreased after YAP was downregulated and elevated when YAP was overexpressed, as demonstrated by Cheng et al. Additionally, activation of the Hippo pathway was shown to suppress the stemness of EC, while loss of Hippo pathway signaling promoted the maintenance and expansion of CSCs ( 47 ). Calmodulin and E-cadherin in EC cells rose after YAP inhibition, and these trends were reversed after YAP overexpression, proving that Hippo was engaged in the EMT process in EC and then maintained the stemness of tumor cells ( 12 ).…”

Section: Hippo Pathway and Ecmentioning

confidence: 89%

The Hippo pathway in endometrial cancer: a potential therapeutic target?

Shen,

Li,

Sun

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Endometrial cancer, one of the most prevalent malignant cancers tumors of the female reproductive tract, has been increasing in incidence and mortality rates around the world. The Hippo pathway, one of the eight traditional human cancer signaling pathways, is an intricate signaling network that regulates cell proliferation, differentiation, and migration as well as restricting organ size in response to a range of intracellular and extracellular signals. Inhibiting the Hippo pathway results in aberrant activation of its downstream core component YAP/TAZ, which can enhance cancer cells’ metabolism and maintain their stemness. Additionally, the Hippo pathway can modulate the tumor microenvironment and induce drug resistance, where tumorigenesis and tumor progression occur. However, the Hippo pathway has been little researched in endometrial cancer. Here, we aim to review how the Hippo pathway contributes to the onset, development and the potential treatment of endometrial cancer with the aim of providing new therapeutic targets.

show abstract

RNA Binding Protein RNPC1 Suppresses the Stemness of Human Endometrial Cancer Cells via Stabilizing MST1/2 mRNA

Cited by 5 publications

References 18 publications

NMT1 Enhances the Stemness of NSCLC Cells by Activating the PI3K/AKT Pathway

NMT1 Enhances the Stemness of NSCLC Cells by Activating the PI3K/AKT Pathway

Prognostic Values From Integrated Analysis of the Nomogram Based on RNA-Binding Proteins and Clinical Factors in Endometrial Cancer

The Hippo pathway in endometrial cancer: a potential therapeutic target?

Contact Info

Product

Resources

About